Hodgkins Lymphoma Market

Key Highlights

• The disease epidemiology covered in the report provides historical as well as forecasted Hodgkin’s Lymphoma epidemiology scenario in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom, and Japan from 2019 to 2032.

• According to the National Organization of Rare Diseases (NORD), the majority of individuals with the adult form of Hodgkin’s disease are between 15 and 40 years of age at the time of diagnosis. A smaller number of individuals are affected after the age of 50. Hodgkin’s disease may also affect children. HL disease accounts for less than 1% of all cases of cancer in the United States.

• Hodgkin’s Lymphoma epidemiology is segmented as Total Incident Cases, Age-specific incident Cases, Gender-specific incident Cases, Incident Population of Relapsed/ Refractory form, and Treatable cases of Relapsed/ Refractory in the Hodgkin’s Lymphoma market report.

• Hodgkin’s Lymphoma market companies are working in the market as Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals, 4SC, TG Therapeutics, and others.

Request a sample to unlock the CAGR for Hodgkin’s Lymphoma Market

DelveInsight's "Hodgkin’s Lymphoma — Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Hodgkin’s Lymphoma, historical and forecasted epidemiology as well as the Hodgkin’s Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.

The Hodgkin’s Lymphoma market report provides current treatment practices, emerging drugs, Hodgkin’s Lymphoma market share of the individual therapies, current and forecasted Hodgkin’s Lymphoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hodgkin’s Lymphoma treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, Spain, Italy, and France) and the United kingdom
• Japan

Study Period: 2019-2032

Hodgkin’s Lymphoma Market Disease Understanding and Treatment Algorithm

The DelveInsight’s Hodgkin’s Lymphoma market report gives a thorough understanding of Hodgkin’s Lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. According to the National Organization for Rare Diseases, Hodgkin's disease comprises of a group of cancers, which are known as lymphoma. Lymphoma is a general term used to describe cancers that affect the lymphatic system, especially the lymph nodes. Tumors often form in the lymph nodes and/or the area around the nodes.

With the help of some preliminary research, it has been seen that Hodgkin lymphoma can result due to multifactorial causes. These are due to an infectious agent, such as a virus (e.g., Epstein Barr Virus). Recent studies indicate that there may be a genetic susceptibility to Hodgkin’s disease in the young adult form of the disorder as well, environmental factors or immune system deficiencies may also play a role in the development of Hodgkin’s disease. Usually, the first sign of Hodgkin’s disease is a swollen lymph node. Two-thirds of the time, a lymph node in the neck is affected. Otherwise, lymph nodes in the armpits, chest, groin, or abdomen are affected. The disease may also spread to other lymph nodes, the area around the nodes, the spleen, liver, lungs, and bone marrow.

Hodgkin’s Lymphoma Diagnosis

A diagnosis of Hodgkin's disease is suspected, based upon a thorough clinical evaluation, a detailed patient history, and identification of characteristic findings (swollen lymph nodes, flu-like symptoms, etc.). A diagnosis may be confirmed by surgical removal and microscopic examination (biopsy) of tissue from a lymph node. The tissue is studied to determine whether particular cells called Reed-Sternberg cells are present.

Hodgkin’s Lymphoma Treatment

Treatment of Hodgkin's disease depends on the stage of the disease. Radiotherapy and/or chemotherapy are the two main treatment options. Chemotherapy and radiation therapy are the main treatments for Hodgkin Lymphoma. Depending on the case, one or both of these treatments might be used. Certain patients might be treated with immunotherapy or with a stem cell transplant, especially if other treatments have not worked. Except for biopsy and staging, surgery is rarely used to treat the condition.

Hodgkin’s Lymphoma Epidemiology

The Hodgkin’s Lymphoma epidemiology section provides insights about historical and current Hodgkin’s Lymphoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• The disease epidemiology covered in the report provides historical as well as forecasted Hodgkin’s Lymphoma epidemiology scenario in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom, and Japan from 2019 to 2032.

• According to the National Organization of Rare Diseases (NORD), the majority of individuals with the adult form of Hodgkin’s disease are between 15 and 40 years of age at the time of diagnosis. A smaller number of individuals are affected after the age of 50. Hodgkin’s disease may also affect children. HL disease accounts for less than 1% of all cases of cancer in the United States.

• The disease epidemiology covered in the report provides historical as well as forecasted Hodgkin’s Lymphoma epidemiology [segmented as Total Incident Cases of Hodgkin’s Lymphoma, Age-specific incident Cases of Hodgkin’s Lymphoma, Gender-specific incident Cases of Hodgkin’s Lymphoma, Incident Population of Relapsed/ Refractory form of Hodgkin Lymphoma, and Treatable cases of Relapsed/ Refractory Hodgkin Lymphoma (R/R HL)] in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom, and Japan from 2019 to 2032.

Country Wise- Hodgkin’s Lymphoma Epidemiology

This section provides a glimpse of the Hodgkin’s Lymphoma epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom, and Japan.

Learn more about the evolving epidemiology trends and key developments: Hodgkin's lymphoma Epidemiology Forecast

Hodgkin’s Lymphoma Drug Chapters

The drug chapter segment of the Hodgkin’s Lymphoma report encloses the detailed analysis of Hodgkin’s Lymphoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hodgkin’s Lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Hodgkin’s Lymphoma Marketed Drugs

Monoclonal antibodies such as Brentuximab vedotin (Adcetris), an anti-CD30 antibody attached to a chemo drug is also used to treat the condition. The antibody acts like a homing signal, bringing the chemo drug to the lymphoma cells with CD30 on them. The drug enters the cells and kills them when they try to divide into new cells. Rituximab (Rituxan) may be used to treat nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This mAb attaches to a substance called CD20 on some types of lymphoma cells.

Additionally, immune checkpoint inhibitors such as Nivolumab (Opdivo) and pembrolizumab (Keytruda) are used in people with classic Hodgkin lymphoma whose cancer has grown during treatment (called refractory cancer) or has returned after other treatments have been tried (called recurrent or relapsed cancer).

Note: Detailed Current therapies assessment will be provided in the full report of Hodgkin’s Lymphoma

Hodgkin’s Lymphoma Emerging Drugs

ADC Therapeutics is developing Camidanlumab Tesirine (ADCT-301), which is in phase II clinical developmental trial for the treatment of Relapsed/Refractory Hodgkin Lymphoma (R/R HL). ADCT-301 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 (HuMax-TAC, licensed from Genmab), conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin. Once attached to a CD25-expressing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead. In addition to CD25-expressing tumor cells, ADCT-301 depletes CD25-positive Tregs in the local tumor environment, which enhances immune-mediated anti-tumor activity. In July 2020, the company declared that the FDA has lifted the partial clinical hold that was placed on the phase II clinical trial of the drug in patients with R/R HL due to lack of information regarding this trial. Additionally, the company highlighted that the drug has shown 31.7% of overall response rate. Currently, the drug is being evaluated in several Hodgkin’s Lymphoma clinical trials. Studies include a pivotal phase II clinical trial in patients with relapsed or refractory (R/R) Hodgkin lymphoma; a phase Ia/Ib clinical trial in patients with R/R Hodgkin lymphoma and non-Hodgkin lymphoma. Recently, in June 2021, the company reported interim results from the pivotal phase II study. The results demonstrated ORR of 66.3% with a CRR of 27.7% and PRR of 38.6%. Median duration of response has not been reached and no new safety signals had been identified. The most common grade ≥3 treatment-emergent adverse events in ≥5% of patients were hypophosphatemia (7.7%), maculopapular rash (6.8%), thrombocytopenia (6.8%), anemia (6.0%) and lymphopenia (6.0%). Nine patients (7.7%) were able to proceed to HSCT following Cami treatment. 6% patients developed Guillain-Barre syndrome/Polyradiculopathy (consistent with the incidence in the Phase I Hodgkin lymphoma patients).

Tislelizumab (BGB-A317) is an investigational humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. Binding to FcγR on macrophages has been shown to compromise the antitumor activity of PD-1 antibodies through activation of the antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and it could serve as a key element of their immuno-oncology combination platform. As per the company’s pipeline portfolio, the drug has been filed for relapsed or refractory classical Hodgkin Lymphoma (R/R HL), which has been granted conditional approval for the treatment of patients with classical Hodgkin’s lymphoma (cHL) who received at least two prior therapies by the China National Medical Products Administration. Currently, Tislelizumab is in a pivotal Phase II Hodgkin’s Lymphoma clinical trial in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).

Note: Detailed emerging therapies assessment will be provided in the full report of Hodgkin’s lymphoma

Learn more about the emerging therapies and key companies active in the therapeutics segment: Hodgkin's lymphoma Pipeline Insight

Hodgkin’s Lymphoma Market Outlook

For Hodgkin lymphoma, radiation is often given after chemotherapy, especially when there's a large or bulky tumor mass (usually in the chest). Radiation therapy namely Involved site radiation therapy (ISRT), Involved field radiation therapy (IFRT), Extended field radiation and total body radiation are commonly employed.

Chemo for Hodgkin lymphoma combines several drugs because different drugs kill cancer cells in different ways. The combinations used to treat the condition are often referred to by abbreviations. ABVD is the most common regimen used in the United States that includes the chemotherapeutic drugs namely Adriamycin (doxorubicin), Bleomycin, Vinblastine and Dacarbazine (DTIC). Other common regimens includes BEACOPP [Bleomycin, Etoposide (VP-16), Adriamycin (doxorubicin), Cyclophosphamide, Oncovin (vincristine), Procarbazine and Prednisone], Stanford V [Doxorubicin (Adriamycin), Mechlorethamine (nitrogen mustard), Vincristine, Vinblastine, Bleomycin, Etoposide, Prednisone]. Radiation is given after chemo in the Stanford V regimen. It is sometimes given after the ABVD or BEACOPP regimens. Another drug that can be considered as chemo is brentuximab vedotin (Adcetris). This is an antibody-drug conjugate (ADC), which is a monoclonal antibody attached to a chemo drug.

Stem cell transplants (SCTs) are sometimes used for hard-to-treat Hodgkin lymphoma , such as disease that doesn’t go away completely after chemotherapy (chemo) and/or radiation or lymphoma that comes back after treatment. The drug Leukine, manufactured by Partner Therapeutics, has received approval by the FDA for the treatment of Hodgkin's disease. Other treatments are symptomatic and supportive.

There are a few emerging key players, which are expected to enter the Hodgkin Lymphoma market in the coming years, which includes ADC Therapeutics (ADCT-301), BeiGene (Tislelizumab), Tessa Therapeutics (Autologous CD30) and others. The launch of these therapies is expected during the forecast period of 2019–2032.

According to DelveInsight, Hodgkin’s Lymphoma market in 7MM is expected to witness a change in the study period 2019-2032.

Analyst Commentary

• The pipeline of Hodgkin’s Lymphoma has many potential therapies that are being investigated for the treatment of Hodgkin’s Lymphoma, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Hodgkin’s Lymphoma market in the 7MM. Aside from that, the market size of Hodgkin’s Lymphoma may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

• The market growth of Hodgkin’s Lymphoma may be offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Hodgkin’s Lymphoma Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Hodgkin’s Lymphoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Hodgkin’s Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of Hodgkin’s Lymphoma

Hodgkin’s Lymphoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes Hodgkin’s Lymphoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Hodgkin’s Lymphoma emerging therapies.

Reimbursement Scenario in Hodgkin’s Lymphoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Hodgkin’s Lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hodgkin’s Lymphoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Hodgkin’s Lymphoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Hodgkin’s Lymphoma Market Report

• The report covers the descriptive overview of Hodgkin’s Lymphoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Hodgkin’s Lymphoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Hodgkin’s Lymphoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Hodgkin’s Lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Hodgkin’s Lymphoma market

Hodgkin’s Lymphoma Market Report Highlights

• In the coming years, the Hodgkin’s Lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Hodgkin’s Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Hodgkin’s Lymphoma. The launch of emerging therapies will significantly impact the Hodgkin’s Lymphoma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hodgkin’s Lymphoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Hodgkin’s Lymphoma clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hodgkin’s Lymphoma Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Hodgkin’s Lymphoma Pipeline Analysis
• Hodgkin’s Lymphoma Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Hodgkin’s Lymphoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Hodgkin’s Lymphoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Hodgkin’s Lymphoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Hodgkin’s Lymphoma drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Hodgkin’s Lymphoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Hodgkin’s Lymphoma market size during the forecast period (2019-2032)?
• At what CAGR, the Hodgkin’s Lymphoma market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Hodgkin’s Lymphoma market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Hodgkin’s Lymphoma market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Hodgkin’s Lymphoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What is the historical Hodgkin’s Lymphoma patient pool in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What would be the forecasted patient pool of Hodgkin’s Lymphoma in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Hodgkin’s Lymphoma?
• Out of all 7MM countries, which country would have the highest prevalent population of Hodgkin’s Lymphoma during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Hodgkin’s Lymphoma treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Hodgkin’s Lymphoma in the US, Europe, and Japan?
• What are Hodgkin's Lymphoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Hodgkin’s Lymphoma?
• How many therapies are in-development by each company for Hodgkin’s Lymphoma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Hodgkin’s Lymphoma treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hodgkin’s Lymphoma therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hodgkin’s Lymphoma and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Hodgkin’s Lymphoma?
• What are the global historical and forecasted markets of Hodgkin’s Lymphoma?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Hodgkin’s Lymphoma market
• Organize sales and marketing efforts by identifying the best opportunities for Hodgkin’s Lymphoma in the US, Europe (Germany, Spain, Italy, and France) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Hodgkin’s Lymphoma market
• To understand the future market competition in the Hodgkin’s Lymphoma market